Treating ARDS: new hope for a tough problem.

[1]  S. Jalkanen,et al.  The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. , 2014, The Lancet. Respiratory medicine.

[2]  F. Lublin,et al.  Interferon Beta and Glatiramer Acetate Therapy , 2012, Neurotherapeutics.

[3]  G. Zimmerman,et al.  The acute respiratory distress syndrome. , 2012, The Journal of clinical investigation.

[4]  M. David,et al.  Immunomodulatory functions of type I interferons , 2012, Nature Reviews Immunology.

[5]  S. Deaglio,et al.  Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. , 2011, Advances in pharmacology.

[6]  R. Dijkhuizen,et al.  Interferon-β attenuates lung inflammation following experimental subarachnoid hemorrhage , 2010, Critical care.

[7]  L. Belardinelli,et al.  Alterations in Adenosine Metabolism and Signaling in Patients with Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis , 2010, PloS one.

[8]  A. Shahangian,et al.  Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. , 2009, The Journal of clinical investigation.

[9]  S. Jalkanen,et al.  IFN‐β regulates CD73 and adenosine expression at the blood–brain barrier , 2008, European journal of immunology.

[10]  S. Jalkanen,et al.  IFN‐β protects from vascular leakage via up‐regulation of CD73 , 2007, European journal of immunology.

[11]  Michel Mittelbronn,et al.  Identification of Ectonucleotidases CD39 and CD73 in Innate Protection during Acute Lung Injury1 , 2007, The Journal of Immunology.

[12]  R. Hirsch,et al.  EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON , 1987, The Lancet.